Constructive Bio

Constructive Bio is charting unexplored chemical space with its groundbreaking genome writing at scale. A spinout of MRC Laboratory of Molecular Biology (LMB), the company is re-engineering human biology by reprogramming the genetic code of living cells to construct programmable biomolecules.

Courtesy – Constructive Bio

Its platform technologies have already created virus-resistant organisms and are turning living cells into sustainable bio-factories to realise the sustainable materials and therapies of the future.

The company’s advanced biopolymers have numerous potential applications, from novel therapeutics and new-generation pharmaceuticals to agriculture, manufacturing and sustainable biomaterials.

Constructive Bio launched with a $15 million seed funding round led by Ahren Innovation Capital, with investment from Amadeus Capital Partners, OMX Ventures and General Inception. Nobel Prize winner, Sir Grey Winter joined the board in October 2024 following the first close of the company’s $58m Series A round.

Career opportunities at Constructive Bio

Briony Quested